Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
~ Clinical data from the study to be presented at the Society of Gynecologic Oncology 19th Annual Winter Meeting February 20 – 22nd, 2014 AVAX Technologies, Inc. (other OTC: “AVXT”) today...
AVAX Technologies, Inc. Files Form 10 With SEC PR Newswire PHILADELPHIA, February 4, 2011 PHILADELPHIA, February 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or the...
AVAX Technologies, Inc. Files Form 10 With SEC PR Newswire PHILADELPHIA, Feb. 4, 2011 PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or the...
Now has the Ability to Pursue Funding for a Phase III Clinical Trial for M-Vax(R) Appoints Two New Members to its Board of Directors PHILADELPHIA, Dec. 16 /PRNewswire-FirstCall/ -- AVAX...
PHILADELPHIA, Oct. 30 /PRNewswire-FirstCall/ -- AVAX Technologies, Inc. (OTC:AVXT) (BULLETIN BOARD: AVXT) (the "Company") today announced that on October 24, 2008, it closed a bridge loan...
AVAX Technologies, Inc. (OTC Market: AVXT.OB) presented the results of its phase?I-II trial of MVax?, its autologous, hapten-modified melanoma vaccine, at the annual meeting of...
AVAX Technologies, Inc. (OTC Market:AVXT.OB) today announces it has received FDA approval to begin enrollment into a Phase I-II clinical trial of OVax for patients with...
AVAX Technologies, Inc. (OTC Market: AVXT.OB) announces the appointment of Isabelle Fourthin, MD as Chief Medical Officer for Europe, Middle East and Africa (EMEA). Dr. Fourthin...
AVAX Technologies, Inc. (OTC Market:AVXT.OB) announces that its abstract, entitled, ?Dose-response study of a cryopreserved, autologous, hapten-modified melanoma vaccine...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 1.0E-5 | 0.0001 | 1.0E-5 | 2000 | 1.0E-5 | CS |
| 12 | 9.0E-6 | 900 | 1.0E-6 | 0.0001 | 1.0E-6 | 50924 | 1.12E-6 | CS |
| 26 | 9.0E-6 | 900 | 1.0E-6 | 0.0001 | 1.0E-6 | 25462 | 1.12E-6 | CS |
| 52 | 9.0E-6 | 900 | 1.0E-6 | 0.0001 | 1.0E-6 | 126795 | 9.014E-5 | CS |
| 156 | -9.0E-5 | -90 | 0.0001 | 0.02 | 1.0E-6 | 79191 | 0.00012961 | CS |
| 260 | -0.00199 | -99.5 | 0.002 | 0.02 | 1.0E-6 | 224302 | 0.00483749 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
